Abstract: The present invention discloses that Salmonella enterica serogroup C2-3 serovars cross protect against Salmonella enterica serogroup C1 serovars and vice versa. Therefore, the present invention discloses the use of either a Salmonella enterica serogroup C2-3 serovar or a Salmonella enterica serogroup C1 serovar in the manufacture of a vaccine for administration to poultry to protect against a disorder arising from a Salmonella enterica serogroup C2-3 serovar and/or a disorder arising from a Salmonella enterica serogroup C1 serovar.

Abstract: The present invention discloses that Salmonella enterica serogroup C2-3 serovars cross protect against Salmonella enterica serogroup C1 serovars and vice versa. Therefore, the present invention discloses the use of either a Salmonella enterica serogroup C2-3 serovar or a Salmonella enterica serogroup C1 serovar in the manufacture of a vaccine for administration to poultry to protect against a disorder arising from a Salmonella enterica serogroup C2-3 serovar and/or a disorder arising from a Salmonella enterica serogroup C1 serovar.

Abstract: The invention provides a compound of one of the formulae (A), (B), (C), (D), (E), (F) as herein defined, or a salt thereof, for use in the treatment of a condition associated with increased or decreased HIF levels or activity, or a condition in which an increase or decrease in HIF levels or activity may be beneficial.

Abstract: A method of identifying, screening, characterising or designing a chemical entity, which mimics or binds to FIH, is described. The method comprises comparing a structural model of FIH with a structural model for said chemical entity, wherein said structural model of FIH is derived from structural factors or structural coordinates determined by subjecting to X-ray diffraction measurements a crystal comprising FIH. Such chemical entities may be used in the treatment of a condition associated with increased or decreased HIF levels or activity.

Abstract: A method of identifying an agent which modulates hydroxylation of hypoxia inducible factor (HIF), comprises contacting a HIF asparagine hydroxylase and a test substance in the presence of a substrate of the hydroxylase under conditions in which asparagine in the substrate is hydroxylated in the absence of the test substance; and determining hydroxylation of the substrate. Preferably the substrate is a HIF polypeptide comprising HIF-1?, a fragment thereof comprising Asn 803 of HIF-1? or a peptide analogue of HIF-1? or fragment thereof comprising an asparagine equivalent to Asn 803 of HIF-1? and wherein hydroxylation of Asn 803 or of a said equivalent asparagine is determined.

Abstract: The invention provides a compound of one of the formulae (A), (B), (C), (D), (E), (F) as herein defined, or a salt thereof, for use in the treatment of a condition associated with increased or decreased HIF levels or activity, or a condition in which an increase or decrease in HIF levels or activity may be beneficial.

Abstract: The invention relates to the finding that the VHL tumour suppressor protein regulates hypoxia inducible factor ? subunits, by targeting HIF ? for destruction in normoxic, but not hypoxic cells. The invention provides assays for modulators of this interaction, and peptides based upon HIF ? subunit sequences which may modulate this interaction.